Non-small cell lung cancer: Novel treatment Strategies

Chest

Volumn 112, Issue 4 SUPPL., 1997, Pages 266S-268S

  Frei III, Emil ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; VINDESINE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CIGARETTE SMOKING; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; SMOKING CESSATION;

EID: 0030800655     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Skarin A, Jochelson M, Shelton T, et al. Neoadjuvant chemotherapy in marginally resectable stage III non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266-74
2. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323:940-45
3. Roth JA, Fossella K, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86:673-80
4. Hide DC, Minna JD. Non-small cell lung cancer: part II. Treatment. In: Haskell CM, Canellas GP, Eilber F, et al, eds. Current problems in cancer. St. Louis: Mosby, 1991; 107-54
5. Green MR. Chemotherapy and radiation in the nonoperative management of stage III non-small cell lung cancer: the right chemotherapy works in the right setting. Important Adv Oncol 1993; 125-37
6. Comis RL, Friedland DM. New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Lung Cancer 1995; 12(suppl 2):S63-99
7. Frei E III, Antman K. Combination chemotherapy, dose and schedule. In: Holland JF, Frei E, Bast R, et al, eds. Cancer medicine. 4th ed. Baltimore: Williams and Wilkins, 1996
8. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52:6702-04